NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF

JACC: Heart Failure

Volumn 7, Issue 2, 2019, Pages 158-168

  Daubert, Melissa A ^a,b   Adams, Kirkwood ^c   Yow, Eric ^b   Barnhart, Huiman X ^a,b   Douglas, Pamela S ^a,b   Rimmer, Susan ^b   Norris, Casey ^b   Cooper, Lawton ^d   Leifer, Eric ^d   Desvigne Nickens, Patrice ^d   Anstrom, Kevin ^a,b   Fiuzat, Mona ^a   Ezekowitz, Justin ^e   Mark, Daniel B ^a,b   O'Connor, Christopher M ^a,f   Januzzi, James ^g   Felker, G Michael ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e UNIVERSITY OF ALBERTA   (Canada)

^f INOVA HEART AND VASCULAR INSTITUTE   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

biomarker guided therapy; heart failure with reduced ejection fraction; NT proBNP; reverse remodeling

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); PROTEIN PRECURSOR;

ADULT; ADVERSE EVENT; ARTICLE; CLINICAL OUTCOME; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE VOLUME; HEART VENTRICLE REMODELING; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; TREATMENT DURATION; BLOOD; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DISEASE MANAGEMENT; HEART FAILURE; HEART STROKE VOLUME; HEART VENTRICLE; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

BIOMARKERS; DISEASE MANAGEMENT; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROTEIN PRECURSORS; STROKE VOLUME; VENTRICULAR REMODELING;

EID: 85060223691     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2018.10.014     Document Type: Article

References (21)

1. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J AM Coll Cardiol 62 (2013), e147–e239.
2. Januzzi, J.L. Jr., Rehman, S.U., Mohammed, A.A., et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol 58 (2011), 1881–1889.
3. Fonarow, G.C., Peacock, W.F., Phillips, C.O., et al. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 49 (2007), 1943–1950.
4. Cleland, J.G., McMurray, J.J., Kjekshus, J., et al. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol 54 (2009), 1850–1859.
5. Sachdeva, A., Horwich, T.B., Fonarow, G.C., Comparison of usefulness of each of five predictors of mortality and urgent transplantation in patients with advanced heart failure. Am J Cardiol 106 (2010), 830–835.
6. Anand, I.S., Fisher, L.D., Chiang, Y.T., et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107 (2003), 1278–1283.
7. Bettencourt, P., Azevedo, A., Pimenta, J., Frioes, F., Ferreira, S., Ferreira, A., N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 110 (2004), 2168–2174.
8. Masson, S., Latini, R., Anand, I.S., et al. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 52 (2008), 997–1003.
9. Weiner, R.B., Baggish, A.L., Chen-Tournoux, A., et al. Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study. Eur J Heart Fail 15 (2013), 342–351.
10. Felker, G.M., Ahmad, T., Anstrom, K.J., et al. Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure. J Am Coll Cardiol HF 2 (2014), 457–465.
11. Felker, G.M., Anstrom, K.J., Adams, K.F., et al. Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: a randomized clinical trial. JAMA 318 (2017), 713–720.
12. Douglas, P.S., DeCara, J.M., Devereux, R.B., et al. Echocardiographic imaging in clinical trials: American Society of Echocardiography Standards for echocardiography core laboratories. J Am Soc Echocardiogr 22 (2009), 755–765.
13. Lang, R.M., Badano, L.P., Mor-Avi, V., et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 28 (2015), 1–39.
14. Nagueh, S.F., Smiseth, O.A., Appleton, C.P., et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 29 (2016), 277–314.
15. Zoghbi, W.A., Enriquez-Sarano, M., Foster, E., et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 16 (2003), 777–802.
16. Berger, R., Moertl, D., Peter, S., et al. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol 55 (2010), 645–653.
17. Troughton, R.W., Frampton, C.M., Brunner-La Rocca, H.P., et al. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur Heart J 35 (2014), 1559–1567.
18. Yancy, C.W., Januzzi, J.L. Jr., Allen, L.A., et al. 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction. J Am Coll Cardiol 71 (2018), 201–230.
19. Kubanek, M., Goode, K.M., Lanska, V., Clark, A.L., Cleland, J.G., The prognostic value of repeated measurement of N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction. Eur J Heart Fail 11 (2009), 367–377.
20. Kramer, D.G., Trikalinos, T.A., Kent, D.M., Antonopoulos, G.V., Konstam, M.A., Udelson, J.E., Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol 56 (2010), 392–406.
21. Januzzi, J.L. Jr., Camargo, C.A., Anwaruddin, S., et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95 (2005), 948–954.